Corporate welfare and big pharma

Corporate welfare and drugs companies

The cost of drugs and other medical equipment is of growing concern to both public health systems and private health insurance companies. Regarding the former, pharmaceutical companies can push up the price of drugs in order to artificially boost taxpayer-funded profits.

The most recent example of this has been the case of Martin Shkreli who acquired, and dramatically increased the cost of Daraprim, an anti-malarial drug. After taking over the company, the price of the drug in the US was increased by over 5,000% overnight – from $13.50 to $750 a pill.

Be the first to comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.